Premium
ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels
Author(s) -
Zwarts KY,
Clee SM,
Zwinderman AH,
Engert JC,
Singaraja R,
Loubser O,
James E,
Roomp K,
Hudson TJ,
Jukema JW,
Kastelein JJP,
Hayden MR
Publication year - 2002
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1034/j.1399-0004.2002.610206.x
Subject(s) - abca1 , single nucleotide polymorphism , coronary artery disease , snp , tangier disease , biology , medicine , population , coding region , cholesterol , coronary atherosclerosis , genetics , endocrinology , gene , genotype , environmental health , transporter
The authors have previously shown that individuals heterozygous for ABCA1 mutations have decreased high density lipoprotein cholesterol, increased triglycerides and an increased frequency of coronary artery disease (CAD), and that single nucleotide polymorphisms (SNPs) in the coding region of the ABCA1 gene significantly impact plasma lipid levels and the severity of CAD in the general population. They have now identified several SNPs in non‐coding regions of ABCA1 which may be important for the appropriate regulation of ABCA1 expression (i.e. in the promoter, intron 1 and the 5′ untranslated region), and have examined the phenotypic effects of these SNPs in the REGRESS population. Out of 12 SNPs, four were associated with a clinical outcome. A threefold increase in coronary events with an increased family history of CAD was evident for the G‐191C variant. Similarly, the C69T SNP was associated with a twofold increase in events. In contrast, the C‐17G was associated with a decrease in coronary events and the InsG319 was associated with less atherosclerosis. For all these SNPs, the changes in atherosclerosis and CAD occurred without detectable changes in plasma lipid levels. These data suggest that common variation in non‐coding regions of ABCA1 may significantly alter the severity of atherosclerosis, without necessarily influencing plasma lipid levels.